<p>/PRNewswire/ -- AbelZeta Pharma, Inc.（&#34;AbelZeta&#34;）是一家全球临床阶段的生物制药公司，专注于创新和专有细胞治疗产品的发现与开发，宣布阿斯利康已同意收购 AbelZeta 在中国对 C-CAR031 的 50% 开发和商业化权利，从而使阿斯利康获得全球开发、生产和商业化 C-CAR031 的独占权。根据协议条款，AbelZeta 将有权从阿斯利康获得高达 6.3 亿美元的款项，包括预付款，以及中国 GPC3 项目的开发、监管和销售里程碑付款。</p>
<p>根据与 AbelZeta 的先前协议，阿斯利康拥有 C-CAR031 在中国以外地区的开发、生产和商业化权利。AbelZeta 还可以获得额外的里程碑付款和全球其他地区开发的版税。</p>
<p>&#34;这笔交易反映了我们利用平台技术开发高未满足医疗需求的实体肿瘤新型细胞疗法的承诺，包括肝细胞癌（HCC），并提供了最大化 C-CAR031 全球影响力的机会，&#34;AbelZeta 董事长兼首席执行官 Tony (Bizuo) Liu 表示。</p>
<p>C-CAR031 是一种自体的、靶向糖蛋白 3（GPC3）的嵌合抗原受体 T 细胞（CAR-T）疗法，采用阿斯利康的显性负向转化生长因子-β受体 II 保护平台设计，目前正在研究用于治疗 HCC 和其他实体肿瘤。</p>
<p><strong>关于 HCC</strong> 肝癌是癌症死亡的第三大原因，也是全球第六大常见癌症。几种类型的原发性肝癌发生在成年人中，HCC 是最常见的形式。约 75% 的原发性肝癌为 HCC。肝癌根据起源细胞类型进行分类。HCC 在肝脏中以单个肿瘤或多个小结节的形式开始，在这个局部阶段，可以通过局部靶向或外科方法进行治疗。然而，大多数患者在晚期被诊断，或者他们的疾病进展到晚期 HCC 时预后较差，5 年生存率仅为 7%，中位生存期约为 20 个月。根据 Frost &amp; Sullivan 的数据，预计到 2024 年，中国 HCC 的发病率将稳步增长至约 344,500 例。</p>
<p><strong>关于 AbelZeta Pharma, Inc.</strong> AbelZeta 是一家全球临床阶段的生物制药公司，在美国马里兰州罗克维尔和中国上海设有卓越中心。AbelZeta 专注于开发创新和专有的基于细胞的治疗产品，致力于引入利用自身免疫系统对抗血液恶性肿瘤、炎症和免疫疾病以及实体肿瘤的定制治疗。AbelZeta 在其卓越中心的 GMP 设施中推进研究和开发，拥有多个 CAR-T 疗法的产品管线。</p>
<p><strong>前瞻性声明</strong> 本通讯中与计划、策略、具体活动及其他非历史事实描述相关的声明均为前瞻性声明。前瞻性信息本质上受到风险和不确定性的影响，实际结果可能因众多因素而与当前预期有重大差异。前瞻性声明基于当前的信念和管理层的预期，并受到 AbelZeta Pharma, Inc.（&#34;AbelZeta&#34;或&#34;公司&#34;）控制之外的重大风险和不确定性的影响。鉴于这些不确定性，您不应对这些前瞻性声明过于依赖，这些声明仅在本日期有效。除非法律另有要求，AbelZeta 不承担任何义务，并明确拒绝任何更新、修改或以其他方式修订任何前瞻性声明的义务，无论是书面还是口头，可能会不时作出，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>公司联系人：</strong> Sarah Kelly</p>
<p>传播总监</p>
<p>AbelZeta Pharma, Inc.</p>
<p>+1 (240) 552 5870</p>
<p>[email protected]</p>
<p>www.abelzeta.com</p>
<p>来源 AbelZeta Pharma, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE4Jk5ld3NJdGVtSWQ9U0Y2NDI2NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTgxOTMwUFJfTkVXU19VU1BSX19fX19TRjY0MjY2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE4Jk5ld3NJdGVtSWQ9U0Y2NDI2NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTgxOTMwUFJfTkVXU19VU1BSX19fX19TRjY0MjY2"/></p>

阿斯利康制药

阿斯利康

<p>AbelZeta Pharma, Inc. 宣布阿斯利康将收购其在中国对 C-CAR031 的 50% 权益，该疗法是一种针对 GPC3 的 CAR-T 治疗。该交易包括对 AbelZeta 高达 6.3 亿美元的付款，涵盖预付款、开发、监管和销售里程碑。阿斯利康已经拥有该疗法在中国以外的权利。这项收购旨在增强 C-CAR031 的全球覆盖范围，该疗法正在开发用于治疗肝细胞癌（HCC）和其他实体肿瘤。HCC 是癌症死亡的主要原因，在中国的发病率正在上升</p>

<p>, /PRNewswire/ -- AbelZeta Pharma, Inc. (&#34;AbelZeta&#34;), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, announced that AstraZeneca has agreed to acquire AbelZeta's 50% share of the China development and commercialization rights to C-CAR031, such that AstraZeneca acquires the sole right to develop, manufacture and commercialize C-CAR031 globally. Under the terms of the agreement, AbelZeta will be entitled to receive up to $630 million from AstraZeneca including an upfront payment, and development, regulatory and sales milestone payments for the GPC3 program in China.</p>
<div class="lb-trans"><p>/PRNewswire/ -- AbelZeta Pharma, Inc.（&#34;AbelZeta&#34;）是一家全球临床阶段的生物制药公司，专注于创新和专有细胞治疗产品的发现与开发，宣布阿斯利康已同意收购 AbelZeta 在中国对 C-CAR031 的 50% 开发和商业化权利，从而使阿斯利康获得全球开发、生产和商业化 C-CAR031 的独占权。根据协议条款，AbelZeta 将有权从阿斯利康获得高达 6.3 亿美元的款项，包括预付款，以及中国 GPC3 项目的开发、监管和销售里程碑付款。</p>
</div><p>Under the terms of a prior agreement with AbelZeta, AstraZeneca owns the development, manufacturing and commercialization rights to C-CAR031 in rest of world, outside of China. AbelZeta is also eligible to receive additional milestone payments and royalties for rest of world development.</p>
<div class="lb-trans"><p>根据与 AbelZeta 的先前协议，阿斯利康拥有 C-CAR031 在中国以外地区的开发、生产和商业化权利。AbelZeta 还可以获得额外的里程碑付款和全球其他地区开发的版税。</p>
</div><p>&#34;This transaction reflects our commitment to leverage our platform technology to develop novel cell therapies in solid tumors of high unmet medical need, including Hepatocellular carcinoma (HCC), and provides the opportunity to maximize C-CAR031's global reach&#34; said Tony (Bizuo) Liu, Chairman and CEO of AbelZeta.</p>
<div class="lb-trans"><p>&#34;这笔交易反映了我们利用平台技术开发高未满足医疗需求的实体肿瘤新型细胞疗法的承诺，包括肝细胞癌（HCC），并提供了最大化 C-CAR031 全球影响力的机会，&#34;AbelZeta 董事长兼首席执行官 Tony (Bizuo) Liu 表示。</p>
</div><p>C-CAR031 is an autologous, Glypican 3 (GPC3)-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, designed using AstraZeneca's dominant negative transforming growth factor-beta receptor II armoring platform, and is currently being investigated for the treatment of HCC and other solid tumors.</p>
<div class="lb-trans"><p>C-CAR031 是一种自体的、靶向糖蛋白 3（GPC3）的嵌合抗原受体 T 细胞（CAR-T）疗法，采用阿斯利康的显性负向转化生长因子-β受体 II 保护平台设计，目前正在研究用于治疗 HCC 和其他实体肿瘤。</p>
</div><p><strong>About HCC</strong> Liver cancer is the third-leading cause of cancer death and the sixth most commonly diagnosed cancer worldwide. Several types of primary liver cancer occur in adults, HCC being the most common form. About 75% of all primary liver cancers in adults are HCC. Liver cancers are categorized based on the originating cell type. HCC begins in the liver as either a single tumor or several small nodules and at this local stage, it can be treated by locally targeted or surgical methods. However, most patients are diagnosed at advanced-stage, or their disease progresses to advanced-stage HCC when the prognosis is poor, with a 5-year survival rate of only 7% and a median survival of approximately 20 months. According to Frost &amp; Sullivan, the incidence of HCC in China has been growing steadily to approximately 344,500 cases in 2024.</p>
<div class="lb-trans"><p><strong>关于 HCC</strong> 肝癌是癌症死亡的第三大原因，也是全球第六大常见癌症。几种类型的原发性肝癌发生在成年人中，HCC 是最常见的形式。约 75% 的原发性肝癌为 HCC。肝癌根据起源细胞类型进行分类。HCC 在肝脏中以单个肿瘤或多个小结节的形式开始，在这个局部阶段，可以通过局部靶向或外科方法进行治疗。然而，大多数患者在晚期被诊断，或者他们的疾病进展到晚期 HCC 时预后较差，5 年生存率仅为 7%，中位生存期约为 20 个月。根据 Frost &amp; Sullivan 的数据，预计到 2024 年，中国 HCC 的发病率将稳步增长至约 344,500 例。</p>
</div><p><strong>About AbelZeta Pharma, Inc.</strong> AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies, inflammatory and immunological diseases and solid tumors. AbelZeta advances research and development in its own GMP facilities at its centers of excellence, with a pipeline comprised of multiple CAR-T therapies.</p>
<div class="lb-trans"><p><strong>关于 AbelZeta Pharma, Inc.</strong> AbelZeta 是一家全球临床阶段的生物制药公司，在美国马里兰州罗克维尔和中国上海设有卓越中心。AbelZeta 专注于开发创新和专有的基于细胞的治疗产品，致力于引入利用自身免疫系统对抗血液恶性肿瘤、炎症和免疫疾病以及实体肿瘤的定制治疗。AbelZeta 在其卓越中心的 GMP 设施中推进研究和开发，拥有多个 CAR-T 疗法的产品管线。</p>
</div><p><strong>Forward-Looking Statements</strong> Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to numerous factors. Forward looking statements are based on the current beliefs and management's expectations and are subject to significant risks and uncertainties outside of AbelZeta Pharma, Inc.'s (&#34;AbelZeta&#34; or the &#34;Company&#34;) control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, AbelZeta does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p><strong>前瞻性声明</strong> 本通讯中与计划、策略、具体活动及其他非历史事实描述相关的声明均为前瞻性声明。前瞻性信息本质上受到风险和不确定性的影响，实际结果可能因众多因素而与当前预期有重大差异。前瞻性声明基于当前的信念和管理层的预期，并受到 AbelZeta Pharma, Inc.（&#34;AbelZeta&#34;或&#34;公司&#34;）控制之外的重大风险和不确定性的影响。鉴于这些不确定性，您不应对这些前瞻性声明过于依赖，这些声明仅在本日期有效。除非法律另有要求，AbelZeta 不承担任何义务，并明确拒绝任何更新、修改或以其他方式修订任何前瞻性声明的义务，无论是书面还是口头，可能会不时作出，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Company Contact:</strong> Sarah Kelly</p>
<div class="lb-trans"><p><strong>公司联系人：</strong> Sarah Kelly</p>
</div><p>Director of Communications</p>
<div class="lb-trans"><p>传播总监</p>
</div><p>AbelZeta Pharma, Inc.</p>
<div class="lb-trans"><p>AbelZeta Pharma, Inc.</p>
</div><p>+1 (240) 552 5870</p>
<div class="lb-trans"><p>+1 (240) 552 5870</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.abelzeta.com</p>
<div class="lb-trans"><p>www.abelzeta.com</p>
</div><p>SOURCE AbelZeta Pharma, Inc.</p>
<div class="lb-trans"><p>来源 AbelZeta Pharma, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE4Jk5ld3NJdGVtSWQ9U0Y2NDI2NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTgxOTMwUFJfTkVXU19VU1BSX19fX19TRjY0MjY2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=SF64266&amp;Transmission_Id=202601181930PR_NEWS_USPR_____SF64266&amp;DateId=20260118"/></p>

AbelZeta 宣布将 GPC3 装甲 CAR-T 疗法的剩余中国权益出售给 AstraZeneca